Jan 06, 2022Aldo Mele, MSc
Aldo Mele, MSc, is currently a senior scientist 2 in the diagnostics R&D group for Horizon Discovery, a PerkinElmer company. He obtained his MSc in biotechnology from Columbia University, New York. Before joining Horizon Discovery, he worked in the protein production department at Sanofi-Aventis and the molecular neuro oncology laboratory at The Rockefeller University. His present role at Horizon involves the development of diagnostic reference standards for use in the oncology and prenatal clinical settings.
Molecular diagnostics can be broadly defined as the detection of relevant biomarkers in an individual to study human diseases like cancer, infectious diseases, and congenital abnormalities. The rapid development of diagnostic assays and technologies, such as droplet digital PCR (ddPCR) and next-generation sequencing (NGS), has resulted in the widespread adoption of molecular testing in cancer.
However, there are inherent limitations in running these tests: the quality of analyte, the accuracy and sensitivity of analytical methods, and the reliability and reproducibility of results.
Molecular assays in oncology, including NGS, involve multiple steps, which are prone to biological and technical errors. This calls for the development and use of reference standards to both validate and establish sensitivities of existing cancer diagnostic assays and to aid the development of novel assays.
Tumor mutational profiles
Genetic testing in cancer patients can be largely classified into two categories: cytogenetics and molecular genetics. Though major chromosomal aberrations can be detected by cytogenetics, a deeper insight into specific mutations at the molecular level is important for differential diagnosis, prognosis, and disease management.
A tumor’s mutational profile is primarily comprised of single nucleotide variants (SNVs), which lead to amino acid changes, splicing alterations, or premature truncation of proteins. Small insertions or deletions (INDELs), gene copy number variations, and structural anomalies (e.g., translocations and fusions) are also common DNA aberrations found in the tumor genome.
Tumor profiling tests can detect a single gene or variant, as well as multiple SNVs and other types of mutations. Comprehensive genomic profiling, involving simultaneous testing of multiple genes, is increasingly popular. Analysis of multiple genes improves diagnostic yield and helps stratify patients into different risk groups, allowing more targeted treatment. NGS is widely used in oncology to investigate the underlying molecular mechanisms that cause cancer and detect variants in multiple genes simultaneously from patient samples.
Advances in genome editing, such as CRISPR, has allowed the engineering of highly characterized cell line backgrounds containing these diverse variants of clinical interest. These cell lines can be formulated into renewable and reproducible reference material.
The role of cell line-derived reference standards
Reference standards allow the evaluation of a given assay by verifying that the results are consistent with the expected values of a defined parameter in the control material. However, it is important to ensure commutability of controls with patient samples. Unlike synthetic genes, cell line-derived reference standards offer the genomic complexity of patient samples, which are typically difficult to collect routinely and have variable properties, relevant to a specific disease or cancer type.
Reference standard materials derived from cell lines offer reproducible, renewable, and affordable experimental controls for molecular diagnostic assays. They have evolved from single gene pairs of wild type and corresponding mutant gene variants to multiplexed cocktails of a large number of genes and variants implicated in cancers. These large gene panels are especially useful for identifying new biomarkers linked to uncontrolled cell growth in cancers, and to better characterize genes known to affect cancer growth.